DXCM vs ZBH
Dexcom and Zimmer Biomet, both Healthcare
Dexcom is the larger company at $28B against $17B. On trailing earnings ZBH is the cheaper of the two at a P/E of 21.6 against 33.4, a gap that is only a bargain if the two are growing at similar rates. Over the past year DXCM returned +11% against -10% for ZBH. The RyuScore puts DXCM ahead, 73 against 68 out of 100.
| Figure | DXCM | ZBH |
|---|---|---|
| Last close | $84.10 | $89.12 |
| Market cap | $28B | $17B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 33.4 | 21.6 |
| Dividend yield | n/a | 1.1% |
| 1-year return | +11% | -10% |
| 5-year return | -38% | -32% |
| RyuScoresector-relative, 1–10 | 73/100 | 68/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Dexcom
Revenue of $1.3B in Q2 2026, net income $249M. Its largest reported line is United States, 81% of the disclosed total.
Zimmer Biomet
Revenue of $2.2B in Q2 2026, net income $198M. Its largest reported line is Knees, 38% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.